TY - JOUR
T1 - Single lung transplantation for lymphangioleiomyomatosis
T2 - a single-center experience in Japan
AU - Oishi, Hisashi
AU - Watanabe, Tatsuaki
AU - Matsuda, Yasushi
AU - Noda, Masafumi
AU - Ejima, Yutaka
AU - Saiki, Yoshikatsu
AU - Seyama, Kuniaki
AU - Kondo, Takashi
AU - Okada, Yoshinori
N1 - Publisher Copyright:
© 2018, Springer Nature Singapore Pte Ltd.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Purpose: Lung transplantation is accepted as an effective modality for patients with end-stage pulmonary lymphangioleiomyomatosis (LAM). Generally, bilateral lung transplantation is preferred to single lung transplantation (SLT) for LAM because of native lung-related complications, such as pneumothorax and chylothorax. It remains controversial whether SLT is a suitable surgical option for LAM. The objective of this study was to evaluate the morbidity, mortality and outcome after SLT for LAM in a lung transplant center in Japan. Methods: We reviewed the records of 29 patients who underwent SLT for LAM in our hospital between March, 2000 and November, 2017. The data collected included the pre-transplant demographics of recipients, surgical characteristics, complications, morbidity, mortality and survival after SLT for LAM. Results: The most common complication after SLT for LAM was contralateral pneumothorax (n = 7; 24.1%). Six of these recipients were treated successfully with chest-tube placement and none required surgery for the pneumothorax. The second-most common complication was chylous pleural effusion (n = 6; 20.7%) and these recipients were all successfully treated by pleurodesis. The 5-year survival rate after SLT for LAM was 79.5%. Conclusion: LAM-related complications after SLT for this disease can be managed. SLT is a treatment option and may improve access to lung transplantation for patients with end-stage LAM.
AB - Purpose: Lung transplantation is accepted as an effective modality for patients with end-stage pulmonary lymphangioleiomyomatosis (LAM). Generally, bilateral lung transplantation is preferred to single lung transplantation (SLT) for LAM because of native lung-related complications, such as pneumothorax and chylothorax. It remains controversial whether SLT is a suitable surgical option for LAM. The objective of this study was to evaluate the morbidity, mortality and outcome after SLT for LAM in a lung transplant center in Japan. Methods: We reviewed the records of 29 patients who underwent SLT for LAM in our hospital between March, 2000 and November, 2017. The data collected included the pre-transplant demographics of recipients, surgical characteristics, complications, morbidity, mortality and survival after SLT for LAM. Results: The most common complication after SLT for LAM was contralateral pneumothorax (n = 7; 24.1%). Six of these recipients were treated successfully with chest-tube placement and none required surgery for the pneumothorax. The second-most common complication was chylous pleural effusion (n = 6; 20.7%) and these recipients were all successfully treated by pleurodesis. The 5-year survival rate after SLT for LAM was 79.5%. Conclusion: LAM-related complications after SLT for this disease can be managed. SLT is a treatment option and may improve access to lung transplantation for patients with end-stage LAM.
UR - http://www.scopus.com/inward/record.url?scp=85047664481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047664481&partnerID=8YFLogxK
U2 - 10.1007/s00595-018-1678-z
DO - 10.1007/s00595-018-1678-z
M3 - Article
C2 - 29808303
AN - SCOPUS:85047664481
SN - 0941-1291
VL - 48
SP - 944
EP - 950
JO - Surgery Today
JF - Surgery Today
IS - 10
ER -